Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01937221 · ClinicalTrials.gov registry record
Novel Retinal Imaging Biomarkers in Early Alzheimer's Disease
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 60
- Enrollment target
NCT01937221: Completed study, sponsored by Duke University.
NCT01937221 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01937221 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
Study Summary
The goal of this study is to create new retinal imaging processing software useful for the development of novel retinal biomarkers of cognitive impairment associated with Alzheimer's disease (AD).
Primary Outcome
The study will determine the significance of difference in NFL/GCL score between the AD subject groups at baseline.
Interventions
- OTHER spectral-domain optical coherence tomography (SD-OCT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2013-09 |
| Est. Completion | 2017-07 |
What the finished NCT01937221 record still lists
NCT01937221 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which spectral-domain optical coherence tomography (SD-OCT) is the first listed.
NCT01937221 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01937221 about?
NCT01937221 is a clinical study titled "Novel Retinal Imaging Biomarkers in Early Alzheimer's Disease". The goal of this study is to create new retinal imaging processing software useful for the development of novel retinal biomarkers of cognitive impairment associated with Alzheimer's disease (AD).
What is the current status of trial NCT01937221?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2013-09. Estimated completion is 2017-07.
What interventions are being tested in trial NCT01937221?
The interventions under investigation include: spectral-domain optical coherence tomography (SD-OCT) (OTHER).
Who is sponsoring clinical trial NCT01937221?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia